Sanofi and Google to develop new healthcare Innovation Lab

20 Jun 2019

Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.

Sanofi and Google to develop new healthcare Innovation Lab

“We stand on the forefront of a new age for biology and human health, with the opportunity to transform healthcare through partnerships with pioneering technology and analytics companies,” says Ameet Nathwani, Chief Digital Officer, Chief Medical Officer & Executive Vice President, Medical at Sanofi. “Combining Sanofi’s biologic innovations and scientific data with Google’s industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence (AI), we aspire to give people more control over their health and accelerate the discovery of new therapies.”

The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives: to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

"Life sciences companies are looking to data driven, digital innovation to help fuel the creation of accessible healthcare solutions," said Thomas Kurian, CEO, Google Cloud. "We look forward to collaborating with Sanofi to help accelerate the cycle of healthcare innovation to populations throughout the world."

The Innovation Lab will develop both scientific and commercial solutions

Sanofi and Google will leverage deep analytics across data sets to better understand key diseases and extract related patient insights. This will enable Sanofi to research and develop more personalized approaches to treatment and identify accompanying technologies to improve health outcomes. The companies will apply technology and analytics on Sanofi’s large real world database to better understand what treatments work for patients. This aims to result in an improved ability to offer personalized treatment advice, thus optimizing patient care and reducing healthcare costs.

Sanofi and Google also plan to apply AI across diverse datasets to better forecast sales and inform marketing and supply chain efforts. Using AI will take into account real-time information as well as geographic, logistic and manufacturing constraints to help the accuracy of these complex activities.

In addition, Sanofi IT will be modernizing its infrastructure by migrating some existing business applications to Google Cloud Platform (GCP). By leveraging automation, scalability, and agility — along with increases in data and analytic capabilities — Sanofi will accelerate and simplify legacy management, provide easy access to recent technologies and its integration into business plans. The transition to GCP will maximize operational cost efficiency and support business objectives, including the Innovation Lab.

Read More

Related news

Colorcon launches new $50 million VC Fund

Colorcon launches new $50 million VC Fund

17 Sep 2019

The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment

Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment

13 Sep 2019

New formulation of oxycodone hydrochloride contains the narcotic antagonist naloxone in order to prevent abuse.

Read more 
Mallinckrodt to sell BioVectra for $250 million

Mallinckrodt to sell BioVectra for $250 million

11 Sep 2019

Transaction continues to advance Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business.

Read more 
Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more